ClinicalTrials.gg
RecruitingNCT07093255tROPhy-1Updated Nov 16, 2026

Safety, PK and PD of FLQ-101 in Premature Neonates

A Phase 1 interventional study of FLQ-101 in Retinopathy of Prematurity (ROP), sponsored by FELIQS INC.. Recruiting at 2 sites in United States. Open to participants aged 4 Days to 5 Days. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by FELIQS INC. · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 16, 2026Eligibility revised1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
4 Days to 5 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Retinopathy of Prematurity with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Retinopathy of Prematurity · United States.

Planned enrollment
25th of 32
18 · median 114
Started
2026
with 2 others
Phase 1
3 of 51
1 open now
Registered
48th of 51
by date

Among the 51 studies in Retinopathy of Prematurity with a site in United States, this one is the 25th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 1, and was the 48th registered.

Retinopathy of Prematurity

170 studies on the registry are indexed under Retinopathy of Prematurity; 28 are open to participants now.

Browse Retinopathy of Prematurity studies →

Open to participants now

6 of the 51 studies in Retinopathy of Prematurity with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: 4 Days to 5 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Retinopathy of Prematurity with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.

03

Conditions studied

  • Retinopathy of Prematurity (ROP)
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
4 Days to 5 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consent is obtained from parent(s) or legal guardian.
  • Neonates born at 25 weeks +0 days and 27 weeks +6 days of gestation.

Exclusion criteria

Exclusion Criteria:

  • Neonates with congenital malformation of the eye or any other ocular condition that may prevent or relevantly affect any of the assessments or procedures.
  • Neonates with serious congenital anomalies, severe congenital infection, and chromosomal abnormalities.
  • Neonates who are seriously ill and not expected to survive.
  • Neonates with heart disease, including cardiomyopathy, serious arrhythmias, and congenital heart disease. (Neonates with patent foramen ovale may be included in the study if clinically stable).
  • Neonates that are small for gestational age defined as having a weight \<10th percentile at birth based on the Fenton growth charts for gestational age and sex.
  • Neonates with history of or ongoing intraventricular hemorrhage (IVH) grades 2, 3 or 4. Neonates with IVH grade 1 may be included in the study at the discretion of the PI.
  • Neonates with any other medical conditions or comorbidities or circumstances that in the opinion of the investigator may have a relevant impact on study participation or any of the study assessments or procedures.
  • Infants scheduled to participate in other interventional clinical trials while participating in the study and until reaching end of study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    FLQ-101

    Drug: FLQ-101

Interventions

  • DrugFLQ-101

    The invervention comprises 3 Groups: * Group 1: Low Dose * Group 2: Middle Dose * Group 3: High Dose

06

What researchers measure

Primary outcomes

  1. Frequency of adverse events

    Time frame: Day 1 to 36 weeks PMA(post menstrual age)

Secondary outcomes

  1. Pharmacokinetic parameters of FLQ-101

    Time frame: Day 1 to 24 hours post first oral dose

  2. Pharmacodynamic parameters of FLQ-101

    Time frame: Day 1 to 24 hours post first oral dose

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 30, 2025
StartActual
Apr 3, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Brigham and Women's Hospital · Boston, United States
Nov 16, 2026
Eligibility
1 inclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedNeonates born at 2625 weeks +0 days and 27 weeks +6 days of gestation.
  • RemovedMale or female infants with a birth weight greater than or equal to 650 gm.
Oct 13, 2026
Show all 2 updates
  1. Nov 16, 2026
    1 site added
    Show site
    • Brigham and Women's Hospital · Boston, United States
    + 1 other change: verification date
  2. Oct 13, 2026
    Eligibility 1 inclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedNeonates born at 2625 weeks +0 days and 27 weeks +6 days of gestation.
    • RemovedMale or female infants with a birth weight greater than or equal to 650 gm.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07093255
Lead sponsor
FELIQS INC.
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Apr 3, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Clinical Trial Office
Contact
clinicaltrial@feliqs.com
+81-942-707-330

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion